Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients
about
Modulation of inflammasome activity by Porphyromonas gingivalis in periodontitis and associated systemic diseasesStructure/function studies of human decay-accelerating factorComplement activation by apoptotic endothelial cells following hypoxia/reoxygenationHeterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injuryPeptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptorComplementary recognition of alternative pathway activators by decay-accelerating factor and factor HNeutrophil microdomains: linking heterocellular interactions with vascular injury.Phosphatidylserine exposure and red cell viability in red cell aging and in hemolytic anemia.Development of complement therapeutics for inhibition of immune-mediated red cell destructionScott syndrome erythrocytes contain a membrane protein capable of mediating Ca2+-dependent transbilayer migration of membrane phospholipidsRapid, transient phosphatidylserine externalization induced in host cells by infection with Chlamydia spp.Initiation and regulation of complement during hemolytic transfusion reactions.Neisserial lipooligosaccharide is a target for complement component C4b. Inner core phosphoethanolamine residues define C4b linkage specificity.Expression of CD55 on red blood cells of β-thalassemia patients.An Attempt to Induce Transient Immunosuppression Pre-erythrocytapheresis in a Girl With Sickle Cell Disease, a History of Severe Delayed Hemolytic Transfusion Reactions and Need for Hip ProsthesisStorage lesion: role of red blood cell breakdown.Atypical haemolytic uraemic syndrome in a patient with sickle cell disease, successfully treated with eculizumabFM1-43 reports plasma membrane phospholipid scrambling in T-lymphocytes.Mechanism of induction of complement susceptibility of erythrocytes by spider and bacterial sphingomyelinases.The hypercoagulable status in common Mediterranean β-thalassaemia mutations trait.In vitro evidence of complement activation in patients with sickle cell disease.Phosphatidylethanolamine is progressively exposed in RBCs during storage.Functional alterations of rabbit erythrocytes induced by Loxosceles gaucho venom.
P2860
Q26768562-FC3A6F14-3ACE-41D7-A7AE-9F1E04FEA00EQ28139971-4EB5F585-707A-44E1-B7B1-07D247E56CA2Q28362356-51663014-A64B-4992-9F12-22C5C0A68B4BQ30491404-D06C8A56-4B9A-4CC1-BF08-2386A1DD863DQ33215922-2FF1CC83-1C35-41DE-9CCE-0DBD243DCFE7Q33749851-D3B2EC8F-FA2B-4ABF-A9FC-3F0D60948FEEQ35955374-CB64267F-2B52-4FDC-B1B7-C1732D127251Q35979479-5D1FC79E-DE6F-49A6-AE80-FDDC5087812BQ36222203-9A495117-7182-4B28-B616-61B87D7DE7F4Q37366771-1E01D4F6-A1F0-4495-BB53-177ABAD72C29Q37875003-8C82B351-4339-4F63-97D4-975E4584A442Q38057232-DF576399-D44D-4E35-84D2-67BE26FB28F4Q38349640-49665B25-FFB6-4513-B2DF-1612B0AB8FF1Q39315250-D3FC6F7D-C4B9-44AF-8783-4E9002F1F0C8Q41982475-E10CF714-B141-402B-BF84-3CDBB02A8F91Q42720111-D7A01DA7-2511-484C-ABF3-B67B7EA6AC99Q42738030-4FC591C1-5857-451A-B27A-72079A129929Q42996984-6F3E3E94-9B51-472B-BC6E-9BB6A57F8794Q44133279-2FDDBE43-D6BC-489E-AA09-E6D6B2785AE6Q46434435-22E54086-33A8-48C7-9EE6-0D3EEABC8E0CQ47163783-9B86C376-0D33-46FC-B780-BEBDB6A2247CQ50217742-95842191-6011-4499-8E20-F3B10FF340B9Q50669597-D8D881DE-BDAD-45B1-96C0-672F2B31978F
P2860
Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients
description
1993 nî lūn-bûn
@nan
1993 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Activation of the alternative ...... m sickle cell disease patients
@ast
Activation of the alternative ...... m sickle cell disease patients
@en
type
label
Activation of the alternative ...... m sickle cell disease patients
@ast
Activation of the alternative ...... m sickle cell disease patients
@en
prefLabel
Activation of the alternative ...... m sickle cell disease patients
@ast
Activation of the alternative ...... m sickle cell disease patients
@en
P2093
P2860
P356
P1476
Activation of the alternative ...... m sickle cell disease patients
@en
P2093
P2860
P304
P356
10.1172/JCI116706
P407
P577
1993-09-01T00:00:00Z